Navigation Links
How do anticancer drugs work?

RIVERSIDE, Calif. Anticancer drugs save lives and/or improve the quality of life for many cancer patients. Many anti-cancer drugs work by killing tumor cells after inducing damage to DNA.

The public has an opportunity to learn about the mechanisms of action of some commonly used anticancer drugs and how laboratory research may lead to novel targets and new strategies for cancer treatment.

Yinsheng Wang, a professor of chemistry at the University of California, Riverside, will give a free lecture on May 16 on campus to discuss those drugs that induce damage to DNA, as well as those biomolecules that allow for selective targeting of tumor cells. He will also discuss the implications of personalized medicine in cancer treatment.

Wang's hour-long talk is titled "Curing cancer: How do anticancer drugs work?" It will begin at 5:30 p.m. in Rooms C, D and E, University Extension Center (UNEX). Seating is open. Parking at UNEX is free for lecture attendees.

The lecture is the third in the annual Science Lecture Series hosted by the College of Natural and Agricultural Sciences (CNAS). This year the theme is "The Science of Disease." The series aims to boost the public's awareness and understanding of science and of how scientists work.

"Anti-cancer drugs induce their cytotoxic effects via different molecular targets," Wang said. "Patients' genetic make-up can have a significant effect on the clinical efficacies of anti-tumor drugs. Innovative technologies may lead to the discovery of new molecular targets that can be used for more effective treatment of cancer while minimizing side effects."

Wang is the director of the Environmental Toxicology Graduate Program at UC Riverside. He received his bachelor's degree from Shandong University and master's degree from the Chinese Academy of Sciences. He joined the UCR faculty in 2001, after earning his doctoral degree from Washington University in St. Louis.

He is the recipient of the 2013 Biemann Medal and a 2005 Research Award from the American Society for Mass Spectrometry, as well as the inaugural Chemical Research in Toxicology Young Investigator Award from the American Chemical Society in 2012. He was named a Fellow of the American Association for the Advancement of Science in 2012.

Research in the Wang group is concentrated in two broad areas. The first is DNA damage and repair. His lab uses a variety of chemical and biological tools to understand, at the molecular level, how various kinds of damage to DNA are repaired, and how they affect the flow of genetic information during DNA replication and transcription. His work has brought scientists' understanding of the biological consequences of DNA damage to a new level.

His lab's second research area is proteomics, the study of the functions, structures, and interactions of proteins. His work in this area has led to the discovery of novel mechanisms of action of some anti-tumor drugs and environmental toxicants. In particular, he seeks to understand alterations in the expression of proteins in cells that are treated with anticancer drugs and other agents.

Wang's lecture will be introduced by Aurora Johnson, a physical science teacher in the Moreno Valley Unified School District with 11 years of teaching experience. Previously, she worked in the Riverside and Palm Springs Unified School Districts. She was educated at Riverside City College, Grand Canyon University, and UCR.


Contact: Iqbal Pittalwala
University of California - Riverside

Related biology news :

1. 11th International Congress on Targeted Anticancer Therapies
2. Harnessing anticancer drugs for the future fight against influenza
3. High levels of TRAIL protein in breast milk might contribute to anticancer activity
4. Mapping of cancer cell fuel pumps paves the way for new drugs
5. Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes
6. Cholesterol rafts deliver drugs inside cancer cells
7. Findings to help in design of drugs against virus causing childhood illnesses
8. KU Leuven lab coordinates €9m effort to find new deep-sea drugs
9. Mood-modifying drugs for humans also alter fish behavior
10. Study finds potential to match tumors with known cancer drugs
11. £6.5M in funding to help manufacture the drugs of the future
Post Your Comments:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology: